MAPT and Alzheimer disease: The visual rating method followed in this study was based on the density and distribution of tau identified by the radiotracer [18F]flortaucipir (TauvidTM) which was recently FDA-approved for AD tau pathology at B3-level (Braak stages V/VI)11.